NCT06659640: An ongoing trial by Alnylam Pharmaceuticals
This trial is ongoing. It must report results 2 years, 9 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06659640 |
|---|---|
| Title | A Phase 1/2, Randomized, Double-blind, Placebo-controlled, 2-part Study of the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-6400 in Adult Healthy Volunteers and Multiple Dose ALN-6400 in Adult Patients With Hereditary Hemorrhagic Telangiectasia (HHT) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 7, 2024 |
| Completion date | Jan. 5, 2028 |
| Required reporting date | Jan. 4, 2029, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |